United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Form 10-Q __________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT O ...

Rockwell Medical, Inc. (NASDAQ:RMTI) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET Company Participants Heather Hunter - Senior Vice President and Chief Corporate Affairs Officer Mark Strobeck - President and Chief Executive Officer Paul McGarry - Senior Vice President, Finance and Chief Accounting Officer Conference Call Participants Dipesh Patel - H.C. Wainwright Operator Good morning and welcome to Rockwell Medical's Second Quarter 2023 Results Conference Call and Webcast. Please note this ...

United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q __________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 (Address of principal executive offices) (Zip Code) For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-23661 ROCKWELL MEDICAL, I ...

Financial Data and Key Metrics Changes - Revenue for Q1 2023 was $19.7 million, representing a 22% increase compared to the same period in 2022 and an increase over Q4 2022 [28] - Gross profit for Q1 2023 was $2.6 million, compared to a gross loss of approximately $800,000 for the same period in 2022 [32] - Operating loss for Q1 2023 was $1.4 million, significantly improved from $6.6 million for the same period in 2022 [33] - Net loss for Q1 2023 was $1.75 million or $0.10 per diluted share, compared to a net loss of $7.2 million or $0.84 per share for the same period in 2022 [33] - Cash and cash equivalents at March 31, 2023, were $16.8 million, down from $21.5 million at December 31, 2022, primarily due to fees associated with reacquiring distribution rights from Baxter [38] Business Line Data and Key Metrics Changes - The hemodialysis concentrates business is a major focus, with the company regaining control from Baxter and optimizing purchase arrangements [14][15] - Two long-term supply agreements were signed during Q1 2023, including a multi-million dollar agreement with Concerto Renal Services and another with the largest non-profit dialysis provider in the U.S. [16] - New non-exclusive agreements were established with Cardinal Health and Medline Industries, marking the beginning of many distribution agreements anticipated for the year [17] Market Data and Key Metrics Changes - The international business accounts for approximately 10% of Rockwell's revenue, with sales in various countries across North America, South America, Asia, and Africa [29] - An expansion into the UAE was announced, indicating growth in international markets [19] Company Strategy and Development Direction - The company aims to achieve profitability by 2024 through optimizing its concentrates business and expanding its geographic presence [10][15] - Focus on reducing expenses through operational efficiencies and potential consolidation opportunities within the concentrates space [24][30] - The company is also exploring new product additions that align with its manufacturing capabilities [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the successful transition of the Baxter business and the potential for revenue growth from new agreements [22] - The company reiterated its revenue guidance of $78 million to $82 million and gross profit guidance of $7 million to $9 million for the year [39] - Management highlighted the importance of achieving higher gross margins and the positive trajectory towards profitability [44] Other Important Information - The company has received recognition as a Great Place to Work, reflecting its positive employee experience and culture [43] - The international development of TRIFERIC is ongoing, with partnerships that require no capital expenditure from Rockwell [25] Q&A Session Summary Question: Can you help us think about the gross margin and its potential in a stable environment? - Management indicated that while no specific guidance on gross margin has been issued, the current gross margin is attractive and supports the path towards profitability [42] Question: Can you provide insights on gross profit expectations for the rest of the year? - Management noted the strong performance in Q1 and expressed confidence in continuing to improve gross profit, aligning with the provided guidance [44]

United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q __________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-23661 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its c ...

Financial Data and Key Metrics Changes - For Q4 2022, the company reported revenue of $19.3 million, a 26% increase compared to Q4 2021 [32] - Full-year 2022 revenue reached $72.8 million, representing a 17.6% increase from 2021, marking the highest full-year revenue to date [20][32] - Net cash used in operating activities decreased to $594,000 in Q4 2022 from $9 million in Q4 2021, and for the full year, it reduced to $17.4 million from $33.5 million, a 48% year-over-year reduction [33] - The net loss for Q4 2022 was $2.4 million or $0.20 per share, down from a net loss of $8.9 million or $1.05 per share in Q4 2021 [34] Business Line Data and Key Metrics Changes - The company is transitioning over 700 former Baxter customers to Rockwell, focusing on establishing new agreements with preferred terms [25][27] - The hemodialysis concentrate market is experiencing a shift towards growth as patient census levels off post-COVID, which is expected to increase demand for concentrates [2][3] Market Data and Key Metrics Changes - The U.S. hemodialysis market is currently valued at approximately $380 million and is projected to grow to around $500 million by 2026 [14] - The company anticipates generating revenue between $78 million and $82 million in 2023, reflecting a potential 13% increase over 2022 [57] Company Strategy and Development Direction - The company aims to become the leading global supplier of hemodialysis concentrates, focusing on expanding into new geographies and optimizing agreements with existing customers [21][29] - The strategic decision to terminate the Baxter agreement allows the company to control its own distribution and establish long-term supply agreements [16][51] - The company plans to enhance its financial condition and reduce debt, with a goal of achieving profitability by 2024 [50][62] Management's Comments on Operating Environment and Future Outlook - Management noted that the dialysis market is beginning to recover from a contraction experienced during COVID, with expectations for growth in 2023 [2][3] - The company is focused on reducing expenses and operating more efficiently, with a commitment to finding ways to decrease operational costs [8][21] Other Important Information - The company has successfully completed a $5 million prepayment of its existing loan, reducing long-term debt to $10 million as of December 31, 2022 [56][61] - The company has entered into new supply agreements with major dialysis providers, which include multi-year purchase commitments [59][60] Q&A Session Summary Question: Potential drivers of upside to current 2023 top line guidance - Management highlighted a shift in the dialysis market towards growth and the leveling off of patient census as key drivers for potential revenue increase [2][3] Question: Expectations for fee spending and debt management in 2023 - Management emphasized a focus on operational efficiency and a commitment to reducing expenses while looking for ways to accelerate debt repayment [7][9] Question: Overview of the updated business model and strategy - Management reiterated the goal of becoming a leading supplier in the hemodialysis market and the importance of transitioning former Baxter customers to Rockwell [13][27]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-23661 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 30142 S. Wixom Road, Wixom, Michigan 48393 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE S ...

Rockwell Medical, Inc. (NASDAQ:RMTI) Q3 2022 Earnings Conference Call November 14, 2022 8:00 AM ET Company Participants Heather Hunter - SVP & Chief Affairs Officer Mark Strobeck - President, CEO & Director Paul McGarry - Senior Vice President, Finance and Chief Accounting Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald & Co. Raghuram Selvaraju - HC Wainwright & Co. Operator Good morning, and welcome to Rockwell Medical's Third Quarter 2022 Results Conference Call and Webcast. Please ...

United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q __________________________________________________ (Mark One) Commission File Number: 000-23661 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 38-3317208 (State or other jurisdiction of incorporation or organization) 30142 S. Wixom Road, Wixom, Michigan 48393 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September ...

Financial Performance - Net sales for the three months ended June 30, 2022, were $18.682 million, a 23.5% increase compared to $15.137 million for the same period in 2021[13] - Gross profit for the six months ended June 30, 2022, was $960 thousand, compared to a gross profit of $140 thousand for the same period in 2021, indicating a significant improvement[13] - The company reported a net loss of $4.967 million for the three months ended June 30, 2022, compared to a net loss of $8.400 million for the same period in 2021, reflecting a reduction in losses of 40.5%[13] - For the six months ended June 30, 2022, the net loss was approximately $12.1 million, compared to a net loss of $16.2 million for the same period in 2021, representing a 25.1% improvement[22] - Basic and diluted net loss per share improved to $(0.56) for the three months ended June 30, 2022, compared to $(0.99) for the same period in 2021[13] - The operating loss for the six months ended June 30, 2022, was $11.1 million, an improvement from an operating loss of $15.0 million in the same period of 2021[13] Assets and Liabilities - Total assets increased to $59.116 million as of June 30, 2022, up from $48.574 million as of December 31, 2021, representing a growth of 21.1%[11] - Total liabilities decreased to $38.971 million as of June 30, 2022, from $46.039 million as of December 31, 2021, a decline of 15.3%[11] - Stockholders' equity increased significantly to $20.145 million as of June 30, 2022, compared to $2.535 million as of December 31, 2021, marking an increase of 691.5%[11] - Cash and cash equivalents rose to $30.780 million as of June 30, 2022, compared to $13.280 million as of December 31, 2021, an increase of 131.1%[11] - As of June 30, 2022, the company had approximately $30.8 million in cash and cash equivalents and working capital of $28.7 million[31] Revenue Recognition - The Company recognizes revenue under ASC 606, with revenue from product sales allocated based on stand-alone selling prices[60][63] - Revenue is recognized at the shipping point for the majority of international customers, with payment terms averaging 30 days for customers and 45 days for distributors[66] - Total net revenue for the three months ended June 30, 2022, was $18.682 million, an increase from $15.137 million in the same period of 2021, representing a growth of 23.5%[69] - Drug product sales for the three months ended June 30, 2022, totaled $547,000, compared to $273,000 for the same period in 2021, marking a 100.7% increase[69] - Concentrate product sales for the three months ended June 30, 2022, were $18.135 million, up from $14.864 million in the same period of 2021, reflecting a growth of 21.5%[69] Capital and Financing - The company issued 15,000 shares of preferred stock, raising $14.916 million net of offering costs[17] - The company entered into a sales agreement to offer and sell up to $12.2 million of common stock, with $15.1 million raised from the sale of 7,500 shares at an average price of approximately $2.02[34] - The Company expects to require additional capital to sustain operations and execute its strategic plan for developing FPC for iron deficiency anemia and progressing its pipeline development program[37] - The Company's public float is currently less than $75 million, subjecting it to baby shelf limitations that could restrict its ability to raise capital[38] - The Company received a Notification Letter from Nasdaq indicating non-compliance with the minimum bid price requirement of $1.00 per share for continued listing, which was not met by the deadline of December 8, 2021[39][40] Operational Efficiency - Research and product development expenses decreased to $926 thousand for the three months ended June 30, 2022, down from $2.416 million in the same period of 2021, a reduction of 61.7%[13] - Cash used in operating activities for the six months ended June 30, 2022, was approximately $15.7 million, a decrease from $17.4 million in the prior year[22] - The company reported an increase in accounts receivable of $2.2 million and an increase in inventory of $1.1 million for the six months ended June 30, 2022[22] - The company recognized total stock-based compensation expense of $98,000 for the three months ended June 30, 2022, compared to $433,000 for the same period in 2021[105] Market Position and Strategy - The company is well-positioned for sustainable growth, focusing on providing life-sustaining products for patients with blood disorders and kidney diseases[28] - Rockwell Medical is the second largest supplier of acid and bicarbonate concentrates for dialysis patients in the United States, highlighting its significant market position[24] - The company is developing a next-generation proprietary parenteral iron technology platform, Ferric Pyrophosphate Citrate, aimed at treating iron-deficiency anemia[27] Impact of External Factors - The COVID-19 pandemic has adversely affected the Company's business operations, including sales, marketing, and research and development activities[43] - Current financial and credit market conditions may limit the availability of funding or increase the cost of funding for the Company[44]